My RSS Feeds
An Outstanding Pharmaceutical Stock: Sanofi-Aventis Begins to Soar (SNY)
posted Wednesday, 4 January 2006
When I recommended Sanofi-Aventis again a few days ago, SNY was below 44. The French drug maker is now at 46.81, up again today in double the normal volume. With a low P/E around 13, a decent dividend, and so much upside potential, it's hard to think of a better and safer pharmaceutical investment. But if Accomplia gains FDA approval, look out above! Even without that, this company is a money maker that has become way undervalued. Add on the benefit of this French stock as a hedge against a weakening US dollar (and the dollar will drop!), and you'll find that SNY is one of the smartest investments for aggressive and conservative investors alike.
I say 50 by March - and higher if Accomplia is approved.
Meanwhile, don't overlook Celgene.
For non-pharma stocks, I'm also big on Click Commerce (CKCM), an outstanding company with an undervalued stock. Another strong performer with great potential as an investment is Wisconsin's own Brady Corporation (BRC).
I say 50 by March - and higher if Accomplia is approved.
Meanwhile, don't overlook Celgene.
For non-pharma stocks, I'm also big on Click Commerce (CKCM), an outstanding company with an undervalued stock. Another strong performer with great potential as an investment is Wisconsin's own Brady Corporation (BRC).
comments